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ABSTRACT 
 
     Otitis media (OM) and chronic lung diseases, such as chronic obstructive pulmonary 
disease (COPD), are leading causes of antibiotic prescriptions across the globe and of serious 
economic concern regarding rising healthcare costs in the U.S. These conditions affect billions of 
people globally and cost billions in healthcare dollars annually as well. An in depth understanding 
of these disease processes will lead to more effective therapies and reduced healthcare costs 
overall. Nontypeable Haemophilus influenzae (NTHi) is a major pathogen associated with OM 
and COPD, which are both characterized by inflammation and mucous production at the site of 
infection. Mucous is part of the innate immune defenses against infection, and like other innate 
defenses, mucous production must be tightly regulated across all mucosal tissues to avoid 
deleterious effects and spread of infection. In this dissertation, we show that mice deficient in RIP-
2 have reduced NTHi burden in the middle ear after infection through the tympanic membrane and 
mice deficient in NLRP3 have prolonged infection with NTHi. Our data suggest a role for RIP-2 
in establishing NTHi infection within the middle ear. We also investigate the role of RIP-2 in 
NTHi infection in vitro and in vivo. We show that RIP-2 is a negative regulator of MUC5AC, a 
key mucin produced in the upper respiratory tract, whereas c-Jun N-terminal kinase (JNK) is a 
positive regulator of MUC5AC. Our studies provide evidence that RIP-2 plays a novel role in 
controlling mucous production in upper respiratory tract. Together, these data suggest that RIP-2 
may be a potential therapeutic target to control mucous production and NTHi infection in mucosal 
tissues.  
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1 INTRODUCTION  
2 1.1 Innate Defenses and Inflammation 
3 In any infection, tight regulation of innate inflammatory pathways is imperative to fight off 
pathogenic invaders while avoiding tissue damage. Pathogen recognition receptors (PRRs) 
recognize pathogen associated molecular patterns (PAMPs), such bacterial cell wall 
components, and initiate cell-signaling cascades to mount an inflammatory response. Heat, 
redness, and swelling are some of the classical hallmarks of inflammation and are caused, in 
part by, release of cytokines and infiltration of leukocytes to the affected area. These 
inflammatory processes are essential in the host’s ability to clear infection. However, 
exacerbated inflammation can be detrimental to the host, causing tissue damage and even 
spread of the infection.  
4  
5 Mucosal barriers in the upper respiratory tract, including the middle ear, typically aide in 
trapping and clearance of infectious agents as a protective mechanism for the host [1]. Mucins 
are a major component of mucous in these regions. Mucins are a family of high molecular 
weight glycoproteins secreted by goblet cells in mucosal tissues. There are more than 20 
known mucins, twelve of which have been found in the respiratory tract [2]. Mucin-5AC 
(MUC5AC) is known to be one of the major mucins produced during respiratory infection 
and otitis media (OM). While appropriate mucous production is protective for the host, 
previous findings have shown mucous overproduction can be deleterious [1-4]. In fact, thick 
mucous and neutrophil nets can create a biofilm-like environment for nontypeable 
Haemophilus influenzae (NTHi), one of the major bacterial pathogens of OM and chronic 
lung diseases, such as chronic obstructive pulmonary disease (COPD). Thickened mucous and 
2 
 2 
overproduction of MUC5AC can lead to persistent, chronic infections or can worsen acute 
injury [1, 5]. Therefore, like inflammation, mucous production must be tightly controlled.  
6  
7 1.2 Respiratory Infection in Mucosal Tissues 
8 Inflammation in the respiratory tract due to infection is included in such diagnoses as COPD 
and OM. COPD is the third leading cause of death in the U.S. with numbers rising each year. 
Hassett et al. reported the annual number of Americans affected by COPD in 2014 at over 14 
million [6]. COPD is defined as any combination of pulmonary diseases, such as pulmonary 
emphysema and chronic bronchitis.  
9  
10 Otitis Media (OM) is one of the most common pediatric infectious diseases in humans 
accounting for over 20 million physician visits and costing the U.S. upwards of 5 billion 
dollars annually [7, 8]. OM is characterized by inflammation in the middle ear cavity with or 
without effusion, with the most severe infections presenting with the latter. COPD and OM 
are most often preceded by a primary upper respiratory viral infection, which allows 
commensal bacterial species colonizing the nasopharyngeal and respiratory tracts to become 
opportunistic pathogens. Nontypeable Haemophilus influenzae (NTHi) is one of the most 
common bacterial pathogens associated with COPD and OM, and currently, the standard 
treatment for both diseases is systemically administered broad-spectrum antibiotics. Surgical 
intervention is also frequently utilized in OM cases by placing tubes to aid in drainage of the 
middle ear cavity in children. This commonplace surgical intervention and frequent use of 
antibiotics warrants concern for the development of drug-resistant strains of bacteria as well 
as the rising healthcare costs associated with these mucosal ailments. Therefore, more 
3 
 3 
innovative and effective treatment options are urgently needed for the treatment of OM in 
pediatric patients and COPD in adults. 
11  
12 1.3 Nontypeable Haemophilus influenzae (NTHi) 
13 NTHi strains are known to cause OM in children and exacerbate COPD in adults [9]. Hi 
species are gram-negative coccobacilli and are serotyped based on the polysaccharide antigen 
in their capsules [10]. The unencapsulated Hi strains are designated nontypeable, because they 
do not produce a positive serum serotype [11]. NTHi has been shown in previous studies to 
target epithelial cells of the upper respiratory system and affect mucociliary clearance in these 
regions via dysregulation of cell signaling pathways [12]. Persistent inflammation has also 
been noted in NTHi infections [11]. NTHi infections are becoming more commonplace with 
the widespread use of the conjugate vaccines for Haemophilus influenzae serotype B (Hib) 
and pneumococcal vaccines [7, 11, 13]. In fact, recent studies indicate invasive species of Hib 
have been eradicated in countries that use the vaccine and NTHi is now the most common 
commensal Hi strain found in both children and adults [13]. Further research is needed to fully 
understand the molecular mechanisms behind exacerbated and prolonged inflammation in 
NTHi infections.  
14  
15 1.4 NLRP3 Inflammasome 
16 Inflammasomes are multimeric cytoplasmic protein complexes that are able to sense a diverse 
network of cellular stress signals, and traditionally, do not sense pathogen associated 
molecular patterns (PAMPs) directly [14]. The NLR family pyrin domain containing 3 
(NLRP3) inflammasome contains NLRP3, an adaptor protein, apoptosis-associated speck-like 
protein (ASC), and the effector cysteine protease, caspase-1 [14]. NLRP3 inflammasome is 
4 
 4 
responsible for cleavage of two critical inflammatory signaling molecules, IL-1β and IL-18, 
into their active forms via autolytic cleavage of pro-caspase-1. NLRP3 inflammasome also 
regulates important tissue repair processes, such as pyroptosis [15]. IL-1β and IL-18 can 
induce a variety of pro-inflammatory responses to combat infection, such as cell proliferation, 
recruitment of leukocytes to the site of infection, as well as activation and polarization of T-
cell responses [16]. NLRP3 inflammasome is essential for optimal nuclear factor-κB (NF-κB) 
activation and has been shown to be vital in clearing numerous types of pathogens, including 
NTHi [17, 18]. In fact, mice defective in functional inflammasome complexes show increased 
middle ear inflammation and reduced ability to clear NTHi in an OM model [19, 20].  
17  
18 The mechanisms underlying NLRP3 inflammasome activation are still being heavily 
researched, and kinase involvement in NLRP3 inflammasome activation has only recently 
been demonstrated [21]. Numerous possible phosphorylation sites on ASC have been 
identified [21] indicating several kinases may be involved in inflammasome activation. It is 
imperative to understand the mechanisms by which the NLRP3 inflammasome is activated as 
novel therapeutic targets may be used to control inflammation during the infection process.  
19  
20 1.5 Receptor Interacting Protein (RIP)-2 
21 RIP-2 plays a key role in NF-κB activation, and previous studies have shown that RIP-2 may 
be involved in regulating the NLRP3 inflammasome [22, 23]. Nucleotide-binding 
oligomerization domain 1 and 2 (NOD1 and NOD2) are cytosolic receptors upstream of the 
NLRP3 inflammasome that detect bacterial peptidoglycans, most notably muramyl dipeptide 
(MDP) from the cell walls of bacteria [24]. Upon NOD1/2 detection of PAMPs, they recruit 
and interact with RIP-2 via their CARD domains [25]. RIP-2 is a dual-specificity kinase 
5 
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downstream of NOD1/2, which undergoes autophosphorylation and subsequent 
polyubiquitination to drive NF-κB transcription of inflammatory cytokines and chemokines 
[24], including NLRP3 for inflammasome formation. RIP-2 plays a key role in activation of 
multiple inflammatory signaling cascades, including NF-κB and mitogen-activated protein 
kinase (MAPK). RIP-2 is not required for NF-κB activation but is an essential signaling 
adaptor, and previous studies have shown NF-κB activation is sub-optimal in its absence [26].  
22  
23 Interestingly, a recent study showed two kinases are able to modulate phosphorylation of ASC 
in inflammasome complexes and identified numerous residues as possible phosphorylation 
sites [29]. RIP-2 has not yet been fully investigated as a possible activator of the 
inflammasome, though RIP-2 has been shown to interact with components of the 
inflammasome during early inflammasome formation. Fully understanding the mechanisms 
by which inflammasome activation occurs will lead to novel therapeutic targets to control 
inflammatory processes downstream of the inflammasome and treat exacerbated 
inflammation.  
24  
25 1.6 Summary 
26 Mucosal barriers within the respiratory system, and others such as the gastrointestinal tract, 
exist to trap invading pathogens and protect the host from infection. However, if infection 
occurs, induction of inflammatory pathways is essential to fight these pathogens. Tight 
regulation of inflammation and mucous production is critical for the clearance of bacterial 
pathogens and to avoid tissue damage and exacerbated disease states. In NTHi infections, 
exacerbated and prolonged inflammation is often seen at the site of infection. Further research 
6 
 6 
is needed to fully understand the mechanisms underlying this exacerbated and prolonged 
inflammation in NTHi infections.  
27  
28 The goal of this dissertation work is to investigate the role of RIP-2 and NLRP3 
inflammasome in NTHi clearance and in NTHi-induced mucin MUC5AC expression. 
Specific aim one examines the relationship between NLRP3 inflammasome, RIP-2, and NTHi 
bacterial clearance. This aim will be addressed by investigating 1) if NLRP3 deficient mice 
have prolonged presence of NTHi in the middle ear cavity compared to RIP-2 deficient mice 
or WT counterparts, 2) if NLRP3 gene expression is inducible by NTHi in vitro. Specific aim 
two investigates the role of RIP-2 as a negative regulator of NTHi-induced MUC5AC gene 
expression. This aim will be addressed by 1) determining if NTHi induces RIP-2 expression 
in vitro and in vivo, 2) if RIP-2 acts as a negative regulator for MUC5AC gene expression in 
vitro, 3) if JNK acts as a positive regulator for NTHi-induced MUC5AC expression, 4) if JNK 
affects RIP-2 induction by NTHi, and 5) if NTHi induces b-defensin in vivo, and 6) if RIP-2 
deficient mice exhibit increased inflammation in lung infection model.  
29  
30  
31  
32  
33  
34  
35  
36 Figure 1.1 Mucosal Barrier at Epithelial Cell Surface 
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102 2. Investigation of NTHi-induced NLRP3 
103  
104 2.1 Abstract 
105 Inflammation is needed to clear pathogens associated with otitis media; a leading cause of 
antibiotic prescriptions across the globe and a driving force of rising healthcare costs in the 
U.S. However, exacerbated and uncontrolled inflammation can be detrimental. The NLRP3 
inflammasome has been shown to be essential in the body’s response to nontypeable 
Haemophilus influenzae (NTHi) infection and RIP-2 has been linked to the inflammasome as 
a possible activator of the complex. Here we show that mice deficient in RIP-2 exhibited 
reduced NTHi burden in the middle ear after infection through the tympanic membrane and 
12 
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mice deficient in NLRP3 have prolonged infection. Our data suggest an important role for 
RIP-2 in establishing NTHi infection within the middle ear. 
106  
107 2.2 Introduction 
108 Tight regulation of inflammation is essential in combating pathogenic invaders. Heat, redness, 
and swelling are some of the classical hallmarks of inflammation and are caused by an 
elegantly choreographed cascade of inflammatory signals and key pro-inflammatory players, 
such as cytokines, chemokines, and leukocytes at the site of infection. These inflammatory 
processes are essential in the host’s ability to clear infection. However, exacerbated 
inflammation can be detrimental to the host, causing tissue damage and even spread of the 
infection.  
109  
110 Due to the important role NLRP3 plays in mediating pathogen-induced host immune defense 
responses, we sought to determine the role of NLRP3 in NTHi-induced infection in a well-
established mouse model of otitis media (OM). Both the in vitro and in vivo roles of NLRP3 
will be determined by using NLRP3 deficient mice and human epithelial cells.  
111  
112 As previously mentioned, OM is the of the most common pediatric infectious diseases in 
humans accounting for millions of physician visits and costing billions of healthcare dollars 
annually [1, 2]. NTHi is a part of the upper airway microbiota in healthy individuals and is a 
major human pathogen under opportunistic conditions [3, 4]. NTHi is one of the most common 
bacterial pathogens associated with OM, and frequent antibiotic prescriptions to combat OM 
raise concerns for the development of multi-drug-resistant strains of bacteria as well as the 
rising healthcare costs associated with OM due to surgical interventions that are also 
13 
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commonly utilized in children. Therefore, development of innovative and effective 
therapeutic agents is urgently needed for the treatment of OM in pediatric patients. 
113  
114 Inflammasomes are multimeric cytoplasmic protein complexes which are able to sense a 
diverse network of cellular stress signals and are responsible for cleavage of two critical 
inflammatory signaling molecules, IL-1β and IL-18, into their active forms [5]. The NLRP3 
inflammasome contains NLRP3, an adaptor protein, apoptosis-associated speck-like protein 
(ASC), and the effector cysteine protease, caspase-1 [5]. NLRP3 inflammasome is essential 
for optimal NF-κB activation and has been shown to be vital in clearing numerous types of 
pathogens, including NTHi [6, 7]. In fact, mice defective in functional inflammasome 
complexes show increased middle ear inflammation and reduced ability to clear NTHi in an 
OM model [8, 9].  
115  
116 The mechanisms behind NLRP3 inflammasome activation are still being elucidated, and 
kinase involvement in NLRP3 inflammasome activation has only recently been demonstrated. 
Phosphorylation of Tyr144 in mouse ASC has been established and was required for 
inflammasome activation. Phosphorylation of Tyr144 was blocked by inhibition of SYK and 
JNK kinases [10]. Additionally, numerous possible phosphorylation sites on ASC have been 
identified [10] indicating additional kinases may be involved in inflammasome activation. It 
is imperative to understand the mechanisms by which the NLRP3 inflammasome is activated 
as novel therapeutic targets may be used to control inflammation during the infection process.  
117  
118 RIP-2 is a key adaptor molecule and dual-specificity kinase involved in the activation and 
regulation of critical cell signaling pathways. Upon NOD1/2 detection of PAMPs in the 
14 
 14 
cytosol, they recruit and interact with RIP-2 via CARD domains [11]. RIP-2 is a dual-
specificity kinase downstream of NOD1/2, which undergoes autophosphorylation and 
subsequent polyubiquitination to drive NF-κB transcription of inflammatory cytokines and 
chemokines [12], including NLRP3 for inflammasome formation.  
119  
120 Conflicting reports exist on the involvement of RIP-2 within the NLRP3 inflammasome. RIP-
2 has been shown to interact with pro-caspase-1 to promote cleavage of pro-IL-1β [13]; 
however, in another published report, RIP-2 was found to be a negative regulator of the 
NLRP3 inflammasome during viral infection, and no difference in inflammasome activation 
was reported in Listeria infection in the same study [14]. Additionally, pro-caspase-1 has been 
shown to cleave RIP-2, which inhibited NF-κB activation [15]; thus, the involvement of RIP-
2 in the inflammasome is still not well understood.  
121  
122 Interestingly, a recent study showed the kinases, SYK and JNK, are able to modulate 
phosphorylation of ASC in NLRP3 and AIM2 inflammasome complexes and identified 
numerous tyrosine, serine, and threonine residues as possible phosphorylation sites [16]. RIP-
2 is known to autophosphorylate for protein stability in the NF-κB pathway but has never been 
investigated as a possible activator of the inflammasome via phosphorylation of ASC, though 
both RIP-2 and ASC interact with pro-caspase-1 during early inflammasome formation. It is 
possible that the kinase activity of RIP-2 phosphorylates ASC to activate the inflammasome 
complex upon stimulation with one of its known inducers, such as NTHi. Understanding the 
mechanism of inflammasome activation will lead to novel therapeutic targets to increase 
15 
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activation of the inflammasome in response to infections as well as identify a novel therapeutic 
target to control inflammatory processes downstream of the inflammasome.  
123  
124  
125  
126  
127  
128  
129 2.3 Materials and Methods 
130  
131 2.3.1 Bacterial strains and culture conditions 
132 Clinical isolates of NTHi 12 and bioluminescent NTHi 1885 MEE/pKMLN-1 were used in 
this study. Bioluminescent NTHi 1885 MEE/pKMLN-1 was kindly provided by Dr. Lauren 
O. Bakaletz [17]. NTHi were grown as previously described [18-22]. For in vitro experiments, 
NTHi was resuspended in PBS and used at a multiplicity of infection (MOI) of 50. For in vivo 
experiments, NTHi was resuspended in isotonic saline and used at a concentration of 1 x 107 
CFU per mouse. 
133  
134 2.3.2 Cell culture 
135 Cell culture protocols were previously described [18-26]. All media described below were 
supplemented with 10% by volume FBS (Sigma-Aldrich) and Pen/Strep (100 U/ml penicillin 
and 0.1 mg/ml streptomycin; Life Technologies). Human middle ear epithelial HMEEC-1 
cells were maintained in DMEM (Cellgro) supplemented with BEGM SingleQuots (Lonza). 
16 
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Human bronchial epithelial cells BEAS-2B cells (ATCC) were maintained in RPMI 1640 
medium (Gibco). All cells were cultured at 37°C in 5% CO2. 
136  
137 2.3.3 Real-time quantitative RT-PCR analysis 
138 Total RNA extraction and RT-qPCR were performed as previously described [18-26]. The 
relative quantities of mRNAs were determined by using the comparative Ct method and were 
normalized by using human cyclophilin for in vitro or mouse glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) for in vivo as endogenous controls and primer sequences for 
cyclophilin and GAPDH are previously described [27].The primer sequences of human 
NLRP3 and mouse NLRP3 are as follows: human NLRP3 (Forward:	5’-TCT	CAT	GGA	TTG	
GTG	AAC	AGC-3’,	and	Reverse:	5’-GGT	CCC	CCA	GAG	AAT	TGT	CA-3); mouse NLRP3 (Forward 
5’-CCT TGG ACC AGG TCC AGT GT-3’ and Reverse 5’-AGG CAG CAG TTC ACC AGT 
CT-3’). 
139  
140 2.3.4 Mice and animal experiments 
141 C57BL/6, NLRP3-/-, and RIP-2-/- mice (7–8 wk old) were available from the Jackson 
Laboratory. Anesthetized mice were inoculated transtympanically or intratracheally with 
NTHi at a concentration of 1 × 107 CFU per mouse or saline as control. The inoculated mice 
were anesthetized using isoflurane gas anesthesia at the time points indicated post inoculation 
for in vivo imaging using In vivo Imaging System (Perkin Elmer) and Live Image software. 
Eardrums of mice were inspected for signs of middle ear inflammation. All animal 
experiments were approved by the Institutional Animal Care and Use Committee at Georgia 
State University. 
17 
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142  
143 2.3.5 Statistical analyses 
144 All experiments were repeated in at least three independent experiments. Data are shown as 
mean ± SD of n determinations. Statistical analysis was assessed with two-tailed unpaired 
Student t-test; p < 0.05 was considered statistically significant. 
145  
146 2.4 Results and Discussion 
147  
148 2.4.1 Figure 1. Bacterial Clearance of NTHi in vivo.  
149 Inflammasomes are able to sense a diverse network of cellular stress signals. Specifically, 
NLRP3 inflammasome is responsible for cleavage of two critical inflammatory signaling 
molecules, IL-1β and IL-18, and thus, is needed for a robust inflammatory response against 
invading pathogens. NLRP3 inflammasome is also essential for optimal NF-κB activation and 
has been shown to be vital in clearing numerous pathogens, including NTHi  [6, 7]. RIP-2 
also plays a key role in NF-κB activation. For these reasons, we anticipated both NLRP3-/- 
and RIP-2-/- mice will exhibit deficiencies in clearing NTHi infection. Upon infection of 
bioluminescent NTHi 1885 MEE/pKMLN-1 into the middle ear cavity of C57BL/6, NLRP3-
/-, and RIP2-/- mice via transtympanic membrane injection, mice were imaged using In Vivo 
Imaging System (IVIS).   
150  
151 Interestingly, NLRP3-/- mice showed presence of NTHi at 24 h post infection, while RIP-2-/- 
mice showed clearance of NTHi infection between 9-12 h post infection, which was similar 
to wild type mice. These data indicate possibly RIP-2-/- mice are more efficient at clearing 
18 
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NTHi infection due to some modulation of cell signaling or inflammatory pathways or, 
alternatively, NTHi is not able to remain adhesive to the epithelial surfaces in the middle ear 
cavity of RIP-2-/- mice to establish NTHi infection in this region. Previous reports show RIP-
2 interacts with TRIP6 to potentiate downstream signaling of NF-kB and MAPKs [9], and 
depletion of TRIP6 has been shown to affect actin cytoskeletal  rearrangements in A431 and 
A549 cell lines [10]. Additionally, both NOD2 and RIP-2 knock out mice showed reduced 
levels of cellular adhesion molecules ICAM-1 and VCAM-1 upon stimulation with E. coli to 
the lungs [11].  Interestingly, NTHi has been shown to adhere to ICAM-1 in respiratory 
epithelia and further upregulate it during infection [12]. It’s possible cytoskeletal 
rearrangements or altered expression of cellular adhesion molecules impairs NTHi adhesion 
on the surface of epithelial cells in the middle ear. While the direct relationship between RIP-
2 and cytoskeletal rearrangement or the down regulation of cell adhesion molecules effect on 
bacterial adhesion to respiratory epithelial cells has not been examined, these items may be 
worth looking into in future studies.    
152  
153 We next sought to determine if RIP-2 could be a therapeutic target to promote clearance of 
NTHi; however, current available RIP-2 kinase inhibitors did not show specificity for RIP-2 
activity in our models. Thus, development of highly specific inhibitors is needed in the future 
to fully evaluate the therapeutic potential of inhibiting RIP-2 in treating otitis media. (Please 
see chapter 3 of this dissertation for additional work in RIP2-/- mice). 
154  
155 2.4.2 Figure 2. NTHi induced NLRP3 gene expression in vitro.  
19 
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156 Because induction of host innate immune regulators is known to play a key role in mediating 
inducible host defense response, we next sought to determine if NLRP3 is also inducible in 
our models. As shown in Figure 2A and 2B, NTHi markedly induced NLRP3 gene expression 
in vitro in human epithelial cells. Together our data indicate an important role of NLRP3 as 
well as RIP-2 in NTHi-induced host immune defense responses. Since RIP-2 is known as the 
key regulator of NLRP3, we thus sought to further investigate the role of RIP-2 in NTHi 
infections in Chapter 3. 
157  
158  
159  
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160  
161 Figure 1. Bacterial clearance of NTHi in vivo.  
162 Bioluminescent NTHi 1885 MEE/pKMLN-1 was inoculated into the middle ear cavity of 
C57BL/6, NLRP3-/-, and RIP-2-/- mice via transtympanic membrane injection at a dose of 1 x 
107 CFU. Mice were anesthetized and imaged using In Vivo Imaging System (IVIS).  NLRP3-
/- mice show presence of NTHi at 24 h post infection. RIP-2-/- mice show clearance NTHi 
infection between 9-12 h post infection. 
163  
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164  
165  
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172  
173 Figure 2. NTHi-induced NLRP3 gene expression in vitro.  
174 NTHi induced NLRP3 expression at mRNA level in vitro (A and B). HMEEC-1 (A) and 
BEAS-2B (B) cells were stimulated with NTHi lysate for 5h, and NLRP3 mRNA expression 
analyzed by q-PCR. Data are means ± SD (n = 3); *P<0.05.    
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248 Abstract 
249      Appropriate production of mucous plays a critical role in host innate mucosal defenses 
against infection. However, if uncontrolled, excessive mucous may be detrimental to the host. 
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Mucous production thus must be tightly regulated. In the present study, we investigate the role 
of RIP-2 in regulating nontypeable Haemophilus influenzae (NTHi)-induced up-regulation of 
mucin MUC5AC expression. We show that RIP-2 is a negative regulator of MUC5AC, 
whereas MAP kinase JNK acts as a positive regulator for MUC5AC induction by NTHi. Our 
studies unveil a novel role for RIP-2 in controlling mucous production in upper respiratory 
disease and may shed light on the identification of new therapeutic targets.  
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260 Introduction 
261      Mucosal barriers in the upper respiratory tract, including the middle ear, typically aide in 
trapping and clearance of infectious agents as a protective mechanism for the host [1]. Mucins 
are a major component of mucous in these regions. Mucins are a family of high molecular 
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weight glycoproteins secreted by goblet cells in mucosal tissues. There are more than 20 
known mucins, twelve of which have been found in the respiratory tract [2]. Mucin 5AC 
(MUC5AC) is known to be one of the major mucins produced during upper respiratory 
infections, including otitis media (OM). While appropriate mucous production is protective 
for the host, excessive mucous production can be deleterious [1-4]. In fact, thick mucous and 
neutrophil nets can create a biofilm-like environment for nontypeable Haemophilus influenzae 
(NTHi), one of the major bacterial pathogens of OM and chronic obstructive pulmonary 
disease (COPD). Overproduction of mucin MUC5AC can lead to persistent, chronic 
infections or can worsen acute tissue injury [1, 5]. Therefore, like inflammation, mucous 
production must be tightly controlled.  
262  
263      NTHi-caused upper respiratory infections, including COPD and OM, remain major health 
problems worldwide. COPD is the third leading cause of death in the U.S. with numbers rising 
each year. Hassett et al. reported the annual number of Americans affected by COPD in 2014 
at over 14 million [6]. OM is the most common pediatric infectious disease in humans 
accounting for over 20 million physician visits and costing the U.S. upwards of 5 billion 
dollars annually [7, 8]. OM is characterized by mucous overproduction and inflammation in 
the middle ear cavity due to infection. Pediatric patients are highly susceptible to OM 
pathogens due to the shortened length of the Eustachian tube during development [7]. 
Currently, the standard treatment for both COPD and OM is systemically administered broad-
spectrum antibiotics, which, leads to increased antibiotic resistance. Surgical intervention is 
also frequently utilized in pediatric OM patients by placing tubes to aid in drainage of the 
middle ear cavity. This commonplace surgical intervention and frequent use of antibiotics 
29 
 29 
warrants concern for the development of drug-resistant strains of bacteria as well as the rising 
healthcare costs associated with both inflammatory diseases. Therefore, development of non-
antibiotic therapeutic strategies is urgently needed based on a full understanding of the 
molecular pathogenesis of these inflammatory diseases.  
264  
265      Receptor interacting protein-2 (RIP-2) plays a key role in activation and regulation of 
multiple inflammatory signaling cascades, including nuclear factor-κB (NF-κB) and mitogen-
activated protein kinase (MAPK). Nucleotide-binding oligomerization domain 2 (NOD2) is a 
cytosolic receptor that detects bacterial peptidoglycans and other inflammatory stimuli [9]. 
Upon NOD2 detection of pathogen-associated molecular patterns (PAMPs), RIP-2 is recruited 
and interacts via CARD-CARD interactions. RIP-2 is a dual-specificity kinase downstream 
of NOD-like receptors, which undergoes autophosphorylation and subsequent 
polyubiquitination to drive transcription of inflammatory cytokines and chemokines [9]. RIP-
2 is an essential signaling adaptor, and previous studies have shown NF-κB activation is sub-
optimal in its absence [10]. Previous studies have also shown that RIP-2 acts as an important 
adaptor molecule for ovalbumin-induced lung inflammation [11]. However, the role of RIP-2 
in bacteria-induced expression of mucin MUC5AC, a major contributor of OM and COPD 
pathology, remains largely unknown. 
266  
267      In the present study, we sought to investigate the role of RIP-2 in NTHi-induced MUC5AC 
gene expression. Here we show that NTHi induces RIP-2 expression at mRNA and protein 
levels, and RIP-2 is a negative regulator of MUC5AC expression, whereas c-Jun N-terminal 
kinase (JNK) is a positive regulator for MUC5AC induction. Thus, our study provides the 
30 
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direct evidence for the first time of the negative regulation of MUC5AC induction by NTHi 
via RIP-2 signaling pathway and may lead to the development of new therapeutic strategies 
for suppressing MUC5AC overproduction. 
268  
269 Materials and Methods  
270  
271 Reagents and antibodies 
272      SP600125 was purchased from Calbiochem. Antibodies against β-actin (sc-8432), α-
tubulin (sc-69969) and total JNK1/2 (sc-7345) were purchased from Santa Cruz 
Biotechnology. Antibodies for phospho-JNK1/2 (#9251), anti-rabbit HRP-linked antibody 
(#7074) and anti-mouse HRP-linked antibody (#7076) were purchased from Cell Signaling. 
Antibody against RIP-2 (ab8428) was purchased from Abcam.  
273  
274 Bacterial strains and culture conditions 
275      Clinical isolate of NTHi 12 was used in this study. NTHi were grown as previously 
described [12-16]. For in vitro experiments, NTHi was resuspended in PBS and used at a 
multiplicity of infection (MOI) of 50. For in vivo experiments, NTHi was resuspended in 
isotonic saline and used at a concentration of 1 x 107 CFU per mouse. 
276  
277 Cell culture 
278      Cell culture protocols were previously described [2-4, 12-17]. All media described below 
were supplemented with 10% by volume FBS (Sigma-Aldrich) and Pen/Strep (100 U/ml 
penicillin and 0.1 mg/ml streptomycin; Life Technologies). Human middle ear epithelial 
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HMEEC-1 cells were maintained in DMEM (Cellgro) supplemented with BEGM SingleQuots 
(Lonza). Human bronchial epithelial cells BEAS-2B cells (ATCC) were maintained in RPMI 
1640 medium (Gibco). All cells were cultured at 37°C in 5% CO2. 
279  
280 Real-time quantitative RT-PCR analysis 
281      Total RNA extraction and RT-qPCR were performed as previously described [2-4, 12-17]. 
The relative quantities of mRNAs were determined by using the comparative Ct method and 
were normalized by using human cyclophilin for in vitro or mouse glyceraldehyde-3-
poosphate dehydrogenase (GAPDH) for in vivo as endogenous controls. The primer sequences 
of human MUC5AC, mouse MUC5AC, human cyclophilin and mouse GAPDH were 
described previously [2, 18]. The primer sequences of RIP-2 are as follows: human RIP-2 
(Forward 5’-CAA GCA CGA TAT ATA TAG CTA TGC AG-3’ and Reverse 5’-GCA AAG 
GAT TGG TGA CAT CCT C-3’); mouse RIP-2 (Forward 5’-GGG AAT TTG CAA TGA 
GCC TG-3’ and Reverse 5’-GCA GGA TGC GGA ATC TCA AT-3’).	
282  
283  
284  
285 Plasmids and transfections 
286      RIP-2 siRNA (SR305775) and control siRNA (SR30004) were purchased from Origene. 
All transient transfections were performed using Lipofectamine RNAiMAX (Thermo Fisher 
Scientific) according to the manufacturers’ instructions. For experiments with inhibitors, the 
transfected cells were pretreated with or without chemical inhibitors for 1 h followed by 5 h 
of incubation with NTHi. 
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287  
288 Western blot 
289      Western blot procedures were previously described [2-4, 12-17]. Western blots were 
performed using whole-cell extracts, separated on 8-10 % SDS-PAGE gels, and transferred to 
polyvinylidene difluoride (PVDF) membranes. The membrane was blocked with a solution of 
Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) and 5% non-fat dry milk. The 
membrane was then incubated in a 1:2,000 dilution of a primary antibody in 5% bovine serum 
albumin-TBS-T. After three washes in TBS-T, the membrane was incubated with 1:5,000 
dilution of the corresponding secondary antibody in 5% non-fat dry milk-TBS-T. Respective 
proteins were visualized by using Amersham ECL Prime Reagent (GE Healthcare Life 
Science). 
290  
291 Mice and animal experiments 
292      C57BL/6 and RIP-2-/- mice (7-8 weeks old) were purchased from the Jackson Laboratory. 
Anesthetized mice were inoculated with NTHi at a concentration of 1 × 107 CFU per mouse 
or saline as control [2]. The inoculated mice were sacrificed at 6 and 12 h post-inoculation. 
Eardrums of mice were inspected for signs of middle ear inflammation. Dissected mouse 
middle ears were then subjected to total RNA extraction and histologic analyses. All animal 
experiments were approved by the Institutional Animal Care and Use Committee at Georgia 
State University. 
293  
294 Histology 
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295      As previously described [2], formalin-fixed paraffin-embedded mouse middle ear tissues 
were sectioned (4 µm), and then stained with hematoxylin and eosin (H&E) to visualize 
inflammatory responses and pathological changes in the middle ear. Images of stained cells 
and tissue sections were recorded with light microscopy system (Carl Zeiss). 
296  
297 Statistical analyses 
298 All experiments were repeated in at least three independent experiments. Data are shown as 
mean ± SD of n determinations. Statistical analysis was assessed with two-tailed unpaired 
Student t-test; p < 0.05 was considered statistically significant. 
299  
300 Results and Discussion 
301 NTHi induces RIP-2 in human epithelial cells in vitro and in mouse middle ear in vivo.  
302      RIP-2 is a dual specificity kinase known to modulate inflammatory signaling pathways. 
Previous studies have shown the role of RIP-2 to be complex in various diseases. For example, 
RIP-2 deficient mice were shown to be resistant to developing arthritis and autoimmune-
mediated cephalomyelitis associated with a multiple sclerosis model [9, 19, 20]. 
Paradoxically, dysregulation of the NOD2/RIP-2 pathway has been implicated in 
dysregulation of cell signaling pathways during viral infection [9, 21]. To investigate the role 
of RIP-2 in NTHi-induced mucin expression in our experimental models, we first examined 
whether NTHi induces RIP-2 in vitro. We treated human epithelial cells with NTHi and 
measured RIP-2 mRNA expression by performing quantitative PCR (Q-PCR) analysis. NTHi 
induced RIP-2 expression at mRNA level in human middle ear epithelial HMEEC-1 cells 
(Figure 1A) and human bronchial epithelial BEAS-2B cells (Figure 1B). We also confirmed 
34 
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a time-dependent induction of RIP-2 at the protein level (Figure 1C). Consistent with in vitro 
findings, NTHi-induced RIP-2 mRNA expression was also confirmed in the middle ear of 
mice by q-PCR analysis (Figure 1D). Collectively, these results that NTHi induces expression 
of RIP-2 in vitro and in vivo. 
303  
304 RIP-2 acts as a negative regulator for NTHi-induced MUC5AC expression.  
305      On the basis that mucous overproduction is a hallmark of NTHi-infections and NTHi 
markedly induce RIP-2 expression, we hypothesized that RIP-2 may play a critical role in 
regulating mucin production [22]. To determine the role of RIP-2 in MUC5AC induction, we 
utilized small interfering RNA (siRNA) specific for RIP-2 in human epithelial cells. We first 
evaluated the efficiency of RIP-2 knockdown. As shown in Figure 2A, RIP-2 siRNA 
efficiently depleted RIP-2 expression. Next, we evaluated the effect of siRNA RIP-2 on 
MUC5AC induction. Interestingly, siRIP-2 markedly enhanced NTHi-induced MUC5AC up-
regulation in HMEEC-1 cells (Figure 2B). Moreover, we determined if NTHi also induces 
effusion in the middle ear of the mouse otitis media models. As shown in Figure 2C, increased 
effusion was observed in RIP-2 deficient mice compared with WT control mice as early as 12 
hours post-infection. Together, our data indicate that RIP-2 is a negative regulator for NTHi-
induced MUC5AC expression. 
306  
307 JNK acts as a positive regulator for NTHi-induced MUC5AC up-regulation. 
308      MAP kinase JNK has been shown to play a critical role in mediating bacteria-induced 
inflammatory responses [4, 23]. Thus, we sought to determine the role of JNK in NTHi-
induced MUC5AC expression. We first confirmed the activation of JNK by NTHi. NTHi 
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induced potent activation of JNK in a time-dependent manner in human epithelial cells 
(Figure 3A). We next evaluated the effects of JNK specific inhibitor (SP600125) on NTHi-
induced MUC5AC expression. As shown in Figure 3B, inhibition of JNK suppressed NTHi-
induced MUC5AC expression, thereby indicating a critical role of JNK as a positive regulator 
for NTHi-induced MUC5AC expression.  The role of JNK in regulating bacteria-induced host 
mucosal immune responses is highly complex and may act differently depending on the 
pathogen as well as on the host genes. The positive regulation of MUC5AC expression by 
JNK may be due to its role in mediating the activation of the signaling pathways including the 
transcription factors leading to the transcriptional up-regulation of MUC5AC expression. We 
previously reported that JNK negatively regulates MUC5AC expression via targeting negative 
activator protein-1 (AP-1) site in Streptococcus pneumoniae  infection [4]. Thus, it is possible 
that JNK positively regulates NTHi-induced MUC5AC expression through the AP-1 site in 
the promoter region of MUC5AC gene. Future studies are needed to confirm this hypothesis 
by using AP-1 site mutants of MUC5AC-Luc luciferase reporter promoter constructs.  
309  
310 JNK acts as a negative regulator for NTHi-induced RIP-2 expression. 
311      Having demonstrating the positive role of JNK in mediating the up-regulation of mucin 
MUC5AC by NTHi, we next sought to explore if JNK may also mediate up-regulation of 
MUC5AC by suppressing the expression of RIP-2, the negative regulator for NTHi-induced 
MUC5AC expression. Interestingly, inhibition of JNK using JNK specific inhibitor enhanced 
NTHi-induced expression of RIP-2 (Figure 4). This exciting result provides direct evidence 
to unveil the complex molecular mechanism by which JNK mediates NTHi-induced mucin 
36 
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MUC5AC expression likely via up-regulation of MUC5AC transcription and also via 
inhibition of the induction of negative regulator RIP-2 expression (Figure 5).  
312  
313      Taken together, our studies bring new insights into the complex regulatory mechanism 
underlying bacteria-induced up-regulation of mucous and may be helpful for developing new 
therapeutic strategies for suppressing mucous overproduction in upper respiratory infectious 
diseases. Future studies are needed for further investigating the precise molecular mechanisms 
underlying tight regulation of mucous overproduction. 
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322  
323 Figure 1. NTHi induces RIP-2 in human epithelial cells in vitro and in vivo.  
324      HMEEC-1 (A) and BEAS-2B (B) cells were stimulated with NTHi for 5h, and RIP-2 
mRNA expression was analyzed by Q-PCR analysis. (C) Cells were stimulated with NTHi 
for various time periods (1, 3, 5, or 7h) and RIP-2 protein expression was analyzed by Western 
blot analysis. (D) C57BL/6 mice were transtympanically inoculated with NTHi or control for 
6h, and RIP-2 mRNA expression was analyzed by Q-PCR analysis. Data in A-B, D are means 
± SD (n = 3); *P<0.05. 
325  
Figure 1. NTHi induces RIP-2 expression in vitro and in vivo.
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326  
327 Figure 2. RIP-2 acts as a negative regulator for NTHi-induced MUC5AC expression.  
328      (A & B) HMEEC-1 cells were transfected with siRNA for RIP-2 or control for 40 h and 
were then stimulated with NTHi for 5h and analyzed for RIP-2 (A) and MUC5AC (B) mRNA 
expression by Q-PCR analysis. (C) Middle ear tissue sections from C57BL/6 or RIP-2-/- mice 
transtympanically inoculated with NTHi (1 x 107 CFU) or control were stained with 
hematoxylin and eosin stain, magnification x 200, visualized with Carl Zeiss light microscope. 
Scale bar: 20µm. Data in A-B are means ± SD (n = 3); *P<0.05. 
Figure 2. RIP-2 acts as a negative regulator for MUC5AC expression.
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329  
330 Figure 3. JNK acts as a positive regulator for NTHi-induced MUC5AC expression. 
331      (A) HMEEC-1 cells were treated with NTHi for indicated time periods, and cell lysates 
were analyzed by Western blot analysis with indicated antibodies. (B) HMEEC-1 cells were 
pretreated with 5 µM JNK inhibitor (SP600125) for 1 h followed by stimulation with NTHi 
for 5 h, and MUC5AC mRNA expression was then analyzed by Q-PCR analysis. Data in B 
are means ± SD (n = 3); *P<0.05. 
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Figure 3. JNK acts as a positive regulator for NTHi-induced MUC5AC up-regulation.
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338  
339 Figure 4. JNK acts as a negative regulator for NTHi-induced up-regulation of RIP-2 
Expression.  
340 HMEEC-1 cells were pretreated with 5 µM JNK inhibitor (SP600125) for 1 h followed by 
stimulation with NTHi for 5 h, and RIP-2 mRNA expression was then analyzed by Q-PCR 
analysis. Data are means ± SD (n = 3); *P<0.05. 
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Figure 4. JNK acts as a negative regulator for NTHi-induced RIP-2 expression.
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349  
350 Figure 5. A Schematic diagram illustrating that JNK acts as a positive regulator for 
NTHi-induced up-regulation of mucin MUC5AC expression. In contrast, RIP-2 acts as 
a negative regulator for MUC5AC induction.  
351  
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353 
Figure 5. Schematic model illustrating NTHi-induced MUC5AC is negatively regulated by RIP-2.
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387 Figure 6. NTHi-induced b-defensin gene expression in vivo. 
388 Defensins are part of the innate defenses against microbial invasion. They constitute a family 
of antimicrobial peptides, which interact with the membranes of bacteria based on charge. 
Mouse b-defensin 3 is homologous for human b-defensin 2 and has been shown to be present 
in respiratory tissues [27].  
389  
390 Here we examined C57BL/6 and RIP2-/- mice inoculated with NTHi via transtympanic 
membrane injection into the middle ear.  Mice were sacrificed at 2, 4, and 6 h post inoculation 
and b-defensin mRNA expression analyzed by q-PCR. In Figure 6, RIP-2-/- mice showed 
eight-fold increase in b-defensin 3 mRNA in the middle ear four hours post inoculation with 
NTHi as the WT counterparts (Figure 6). Given the antimicrobial nature of defensins, this 
spike in b-defensin 3 might explain the clearance of bioluminescent NTHi in our study (Figure 
1.1). Further investigation is needed to fully understand the role of b-defensin in RIP-2-/- mice.  
391  
392 Primer sequence for mouse b-defensin 3 is as follows: (Forward:	5’-GTC	TCC	ACC	TGC	AGC	
TTT	TAG-3’,	and	Reverse:	5’-CCA	ATC	TGA	CGA	GTG	TTG	C-3’).	
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406 Figure 6. NTHi-induced b-defensin gene expression in vivo.  
407 C57BL/6 and RIP2-/- mice were inoculated with NTHi at 1 x 107 CFU via transtympanic 
membrane injection into the middle ear.  Mice were sacrificed at 2, 4, and 6 h post inoculation 
and b-defensin mRNA expression analyzed by q-PCR.  
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Figure 6. NTHi-induced β-defensin gene expression in vivo.
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
0 2 4 6	(hr)	
Fo
ld
	In
du
ct
io
n	
BD-3
WT
RIP-2	KO
A
47 
 47 
420 Figure 7. RIP-2 modulates NTHi-induced inflammation in mouse lung. 
421 In Figure 7, lung tissue sections from C57BL/6 or RIP-2-/- mice intratracheally inoculated with 
NTHi or control were stained with hematoxylin and eosin stain. Interestingly, histology from 
lung tissue showed dissimilar results to the histology shown in Figure 3.2 of mouse middle 
ear following infection with NTHi. RIP-2-/- mouse lung tissue shows decreased inflammation 
following infection with NTHi, while WT counterparts show a robust inflammatory response. 
It’s possible the microbiota and resident immune cells in these tissues differ and this may help 
to explain the dissimilarities seen in the histology data. Additional studies are needed to fully 
understand the differences seen here.  
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427  
428 Figure 7. RIP-2 modulates NTHi-induced inflammation in mouse lung.  
429  
430 Lung tissue sections from C57BL/6 or RIP-2-/- mice intratracheally inoculated with NTHi or 
control were stained with hematoxylin and eosin stain, magnification x 100 or x 400, 
visualized with Carl Zeiss light microscope. 
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Figure 7. RIP-2 modulates NTHi-induced inflammation in mouse lung.
A
CON 
W
ild
 T
yp
e 
   
R
IP
2 
-/-
24 h 9 h 
NTHi
100X 400X 100X 400X 100X 400X
49 
 49 
439  
440 4 Conclusion 
441 Otitis media (OM) and chronic lung diseases, such as chronic obstructive pulmonary disease 
(COPD), are major sources of concern for rising healthcare costs, development of multi-drug 
resistant strains of bacteria through repeated antibiotic prescriptions, as well as the pain and 
suffering of patients given these conditions affect billions of people globally. Therefore, it’s 
essential to understand the underlying disease processes and identify novel therapeutic targets 
to better treat these patients and reduce healthcare costs associated with OM and COPD.  
442  
443 Nontypeable Haemophilus influenzae (NTHi) is a major pathogen associated with OM and 
COPD, which are both characterized by inflammation and mucous production at the site of 
infection. NTHi and other Haemophilus strains are present in the normal microbiota of the 
upper respiratory tract. However, under opportunistic conditions, such as during or following 
a primary viral infection, NTHi can take on a pathogenic role in the respiratory tract. Innate 
defenses exist to prevent such infections. Mucosal barriers in the upper respiratory tract, 
including the middle ear, typically aide in trapping and clearance of infectious agents as a 
protective mechanism for the host [1]. While appropriate mucous production is protective for 
the host, previous findings have shown mucous overproduction can be deleterious [1-4], 
actually creating niches for bacteria to form biofilms and even spread infection [5]. 
Additionally, exacerbated and uncontrolled inflammation in these areas can cause irreversible 
tissue damage to the host.  
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445 For these reasons, inflammation and mucous production must be tightly controlled, and as 
such, there exist many regulators of inflammatory pathways, which control pro-inflammatory 
cytokine and chemokine production as well as mucin expression. RIP-2 is an essential 
signaling adaptor protein downstream of the NOD-like receptors, which has previously been 
shown to play a key role in NF-κB activation. RIP-2 undergoes autophosphorylation and 
subsequent polyubiquitination to drive transcription of inflammatory cytokines and 
chemokines [6], including NLRP3 for inflammasome formation. Additionally, RIP-2 plays a 
key role in activation and regulation of multiple inflammatory signaling cascades, including 
NF-κB and MAPK.  
446  
447 Inflammasomes are able to sense a diverse network of cellular stress signals. Specifically, 
NLRP3 inflammasome is responsible for cleavage of two critical inflammatory signaling 
molecules, IL-1β and IL-18, and thus, is needed for a robust inflammatory response against 
invading pathogens. NLRP3 inflammasome is also essential for optimal NF-κB activation and 
has been shown to be vital in clearing numerous pathogens, including NTHi [7, 8]. 
448  
449 In this dissertation work, we sought to determine the role of RIP-2 and NLRP3 inflammasome 
in NTHi clearance and the role of RIP-2 in NTHi-induced MUC5AC expression. Specific aim 
one examined the relationship between NLRP3 inflammasome, RIP-2, and NTHi bacterial 
clearance. Through this work we examined and showed 1) NLRP3 deficient mice have 
prolonged presence of bioluminescent NTHi in the middle ear cavity compared to RIP-2 
deficient mice or WT counterparts and 2) NLRP3 gene expression is inducible by NTHi. 
Specific aim two investigated the role of RIP-2 as a negative regulator of NTHi-induced 
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MUC5AC gene expression. This aim showed 1) NTHi induces RIP-2 expression in vitro and 
in vivo both at mRNA and protein levels; 2) RIP-2 acts as a negative regulator for MUC5AC 
gene expression; 3) JNK positively regulates NTHi-induced up-regulation of MUC5AC 
expression; 4) JNK acts as a negative regulator for NTHi-induced RIP-2 expression, 5) NTHi 
caused induction of b-defensin in vivo in RIP-2 knockout mouse; and 6) RIP-2 deficient mice 
exhibit increased inflammation in lung infection model.  
450  
451 We initially sought to investigate the role of RIP-2 in regulating the NLRP3 inflammasome. 
However, during our initial investigations, we had two interesting observations. First, we were 
unable to attain inducible levels of NLRP3 in vivo in our models, and second, RIP-2-/- mice 
showed reduced loads of NTHi following infection with the bioluminescent NTHi 1885 
MEE/pKMLN-1 into the middle ear via transtympanic membrane injection. Interestingly, 
NLRP3-/- mice showed enhanced presence of NTHi at 24 h post infection, while RIP-2-/- mice 
showed clearance of NTHi infection between 9-12 h post infection, which was similar to wild 
type mice (Ch 2, Fig 1). These data indicate possibly that RIP-2-/- mice are more efficient at 
clearing NTHi infection due to some modulation of cell signaling or inflammatory pathways 
or, alternatively, NTHi cells are less adhesive to the epithelial surfaces in the middle ear cavity 
of RIP-2-/- mice and therefore, unable to establish infection in the middle ear. As previously 
mentioned in chapter 2, depletion of TRIP6 has been shown to affect actin cytoskeletal  
rearrangements [10]. Additionally, the cellular adhesion molecule ICAM-1 is down-regulated 
in RIP-2 deficient mice [11], and NTHi has been shown to adhere to ICAM-1 in respiratory 
epithelia and further upregulate it during infection [12]. While there is currently no direct 
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evidence linking RIP-2 and cytoskeletal rearrangement or the down regulation of ICAM-1 to 
reduced bacterial adhesion, these items may be worth looking into in future studies.    
452  
453 We successfully demonstrated that NTHi-induced NLRP3 gene expression in vitro in human 
epithelial cells (Ch 2, Fig 2A and 2B); however, we were unable to attain NLRP3 induction 
at mRNA levels in vivo after NTHi infection in our models. We next sought to determine if 
RIP-2 could be a therapeutic target to promote clearance of NTHi; however, currently 
available RIP-2 kinase inhibitors did not show high specificity for RIP-2 activity in our 
models.   Further evaluation of our data led us to focus our investigation on the role of RIP-2 
in NTHi-induced OM (chapter 3).  
454  
455 In chapter 3, we’ve shown that RIP-2 is inducible by NTHi both in vitro and in vivo at 
transcriptional and translational levels, indicating a pro-inflammatory role for RIP-2 in NTHi 
infection (Ch 3, Fig 1). Additionally, we showed RIP-2 negatively regulates MUC5AC 
expression, whereas JNK acts as a positive regulator of MUC5AC at least in part via inhibition 
of NTHi-induced RIP-2 expression (Ch 3, Fig 2 and Fig 3).  
456  
457 In Chapter 3, Figure 2, middle ear histology data show that RIP-2-/- mice have onset of 
inflammatory histopathology at earlier time points than wild-type counterparts following 
infection with NTHi. Interestingly, signs of inflammation resolve after 48 hours in RIP-2-/- 
mice while C57BL/6 wild type mice have marked inflammation at similar time points (data 
not shown). This suggests a faster inflammatory response, possibly from alterations in sensing 
PAMPs or cell signaling pathways, from mice deficient in RIP-2 prevents NTHi from being 
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able to successfully infect the middle ear cavity following inoculation through the tympanic 
membrane.  
458  
459 There are several possible explanations for these results, including that NTHi may be less 
adhesive to epithelial cells in RIP-2-/- mice as NTHi is known to target ciliated epithelial cells 
of the respiratory tract [13]. It’s possible RIP-2 affects cytoskeletal arrangement or expression 
of cell surface markers of ciliated cells in the middle ear, and thus, NTHi is impaired in 
establishing infection in mice lacking RIP-2. Additional research is needed to provide direct 
evidence of these, however. An alternative explanation is there is a fast and robust release of 
antimicrobial defenses, such as b-defensin 3. In our study, RIP-2-/- mice showed an eight-fold 
increase in b-defensin 3, a homologue of human b-defensin 2, mRNA in the middle ear four 
hours post inoculation with NTHi as the WT counterparts (Ch 3, Fig 6). Defensins are a family 
of antimicrobial peptides, which might explain the clearance of bioluminescent NTHi in our 
study (Ch 2, Fig 1). Further investigation is needed to fully understand the role of b-defensin 
in RIP-2-/- mice.  
460  
461 Together with the data that RIP-2 is a negative regulator for MUC5AC expression (chapter 
3), it’s possible that increased mucous production in RIP-2-/- mice allows for faster clearance 
of NTHi following infection. Additional studies are needed to fully characterize the role of 
mucin in RIP-2-/- mice and/or to possibly develop a specific inhibitor of RIP-2 should the 
depletion of RIP-2 prove beneficial in the clearance of pathogens from the middle ear.  
462  
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463 In Chapter 3, Figure 7, H&E staining of mouse lung tissue from C57BL/6 and RIP-2-/- mice 
show dissimilar results to the histology shown in Figure 2 (Chapter 3) of mouse middle ear 
following infection with NTHi. RIP-2-/- mouse lung tissue shows decreased inflammation 
following infection with NTHi, while C57BL/6 WT counterparts show a robust inflammatory 
response. It’s possible the microbiota and resident immune cells in these tissues differ and 
these variances may explain the dissimilarities seen in the histology data.  
464  
465 RIP-2 has been shown to be a key signaling adaptor in multiple inflammatory signaling 
pathways. We showed here that RIP-2 may be a potential therapeutic target to control mucous 
production and combat NTHi infection in the middle ear. However, future studies are needed 
to fully understand the role of RIP-2 in clearing NTHi in multiple tissues and mucosal systems. 
It is also important to investigate if increased mucous production through RIP-2 modulation 
of signaling pathways will be beneficial in human patients as any prescribed or over the 
counter medication will most likely be given after infection has begun. Still, the role of RIP-
2 in possibly preventing NTHi from establishing infection in the middle ear is interesting and 
warrants further investigation.   
466  
467 Experimental limitations of this study include lack of a specific inhibitor for RIP-2 and the 
inability to attain inducible levels of NLRP3 in our animal models. Addition of a highly 
specific RIP-2 inhibitor would allow researchers to explore potential pharmaceutical control 
of RIP-2 activity on OM pathology.  
468  
55 
 55 
469 Additionally, our infection models utilize acute models of inflammation. To fully understand 
the chronic nature of OM and diseases like COPD, a dependable chronic inflammation model 
is urgently needed.  
470  
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